Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of cisplatin or carboplatin with durvalumab in limited-stage small cell lung cancer
2020-001050-22Phase 2Active
- Sponsor
- University Medical Center Mainz
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Progression-free survival at 18 months. Started Sep 2020; status: active.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-001050-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001050-22.